Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results.
Incyte (INCY) Q3 2025 earnings beat expectations with $1.37B revenue and $2.26 EPS. Driven by Jakafi and Opzelura growth, the company also raised its full-year 2025 guidance.
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth.
INCYTE CORP (INCY) appears undervalued with strong profitability and a healthy balance sheet. Its low P/E and high ROE suggest a potential value investing opportunity.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Monday. Discover the gap up and gap down stocks in the S&P500 index.
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
jumped 1.5% in the afternoon session after the company announced Health Canada's approval of its Opzelura cream for treating atopic dermatitis in children.
JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the company's shares. On October 9, 2025, JPMorgan analyst Jessica Fye increased Incyte's price target to $89.00, a significant jump from
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Wednesday to uncover the stocks that are gapping in the S&P500 index.
Incyte has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.6%. The stock now trades at $86.01, marking a 38% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by Danish biotech giant Genmab A/S (NASDAQ: GMAB). The all-cash transaction, valued at approximately $8.0 billion, represents
STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights the superior efficacy and safety of its 308nm Excimer laser, specifically the XTRAC® system, when combined with Janus Kinase (JAK) inhibitors
In a recent episode of "Mad Money," Jim Cramer identified several stocks in the S&P 500 that he believes are undervalued, offering growth potential despite the market's record highs.
